Silodosin in the treatment of benign prostatic hyperplasia

Drug Design, Development and Therapy

Volumn 4, Issue , 2010, Pages 291-297

  Rossi, Maxime ^a   Roumeguère, Thierry ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

1A blockers; Benign prostatic hyperplasia; Lower urinary tract symptoms; Silodosin

Indexed keywords

ALFUZOSIN; ANTIHYPERTENSIVE AGENT; DOXAZOSIN; KETOCONAZOLE; PLACEBO; PRAZOSIN; SILDENAFIL; SILODOSIN; TADALAFIL; TAMSULOSIN; TERAZOSIN; ADRA1A PROTEIN, HUMAN; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; INDOLE DERIVATIVE;

AREA UNDER THE CURVE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; FLOPPY IRIS SYNDROME; HUMAN; IRIS DISEASE; LOOSE FECES; LOWER URINARY TRACT SYMPTOM; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PROSTATE HYPERTROPHY; RECOMMENDED DRUG DOSE; RETROGRADE EJACULATION; REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; THIRST; UPPER RESPIRATORY TRACT INFECTION; URINE INCONTINENCE; DISEASE COURSE; DRUG EFFECT; MALE; METABOLISM; MICTURITION DISORDER; PATHOPHYSIOLOGY; PROSTATISM;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; DISEASE PROGRESSION; HUMANS; INDOLES; MALE; PROSTATIC HYPERPLASIA; PROSTATISM; RECEPTORS, ADRENERGIC, ALPHA-1; URINATION DISORDERS;

EID: 79952483524     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S10428     Document Type: Review

References (41)

1. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003;170:530-547.
2. Wasserman NF. Benign prostatic hyperplasia: A review and ultrasound classification. Radiol Clin North Am. 2006;44:689-710.
3. Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet. 2003;361: 1359-1367.
4. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: Focus on the bladder. Eur Urol. 2006;49:651-659.
5. Sountoulides P, van Dijk MM, Wijkstra H, de la Rosette JJ, Michel MC. Role of voiding and storage symptoms for the quality of life before and after treatment in men with voiding dysfunction. World J Urol. 2010;28:3-8.
6. Roehrborn CG, McConnell JD. Benign prostatic hyperplasia: Etiology, pathophysiology, epidemiology, and natural history. In: Wein AJ, Kavoussi LR, Novick AC, et al, editors. Campbell-Walsh Urology. 9th ed. Philadelphia, PA: WB Saunders; 2007.
7. Descazeaud A, Rubin MA, Hofer M, et al. BPH gene expression profile associated to prostate gland volume. Diagn Mol Pathol. 2008; 17:207-213.
8. Price DT, Lefkowitz RJ, Caron MG, et al. Localization of mRNA for three distinct alpha 1-adrenergic receptor subtypes in human tissues: Implications for human alpha-adrenergic physiology. Mol Pharmacol. 1994;45:171-175.
9. 1-adrenoceptor subtypes in human hypertrophied prostate by in situ hybridization. Histochem J. 1996;28:283-288.
10. 11-adrenoceptor subtype mRNAs in human prostate: Comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol. 1996;119:797-803.
11. Forray C, Bard JA, Wetzel JM, et al. The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994;45:703-708.
12. Murata S, Taniguchi T, Takahashi M, et al. Tissue selectivity of KMD- 3213, an alpha (1)-adrenoreceptor antagonist, in human prostate and vasculature. J Urol. 2000;164:578-583.
13. Yamagishi R, Akiyama K, Nakamura S, et al. Effect of KMD-3213, an alpha 1A-adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta. Eur J Pharmacol. 1996;315: 73-79.
14. 1-Adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004;171:1029-1035.
15. Schwinn DA, Roehrborn CG. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol. 2008;15:193-199.
16. ® (silodosin) [Package insert]. Corona, CA: Watson Pharmaceuticals, Inc; 2009.
17. Michel MC, Vrydag W. Alpha1-, alpha2-and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol. 2006;147: S88-S119.
18. Roehrborn CG. Efficacy of α-adrenergic receptor blockers in the treatment of male lower urinary tract symptoms. Rev Urol. 2009;11 Suppl 1: S1-S8.
19. Guimaraes S, Moura D. Vascular adrenoceptors: An update. Pharmacol Rev. 2001;53:319-356.
20. Beduschi MC, Beduschi R, Oesterling JE. Alpha-blockade therapy for benign prostatic hyperplasia: From a nonselective to a more selective alpha1A-adrenergic antagonist. Urology. 1998;51:861-872.
21. 1-adrenoceptors and native tissues. Mol Pharmacol. 1995;48:250-258.
22. 1-Adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213). Yakugaku Zasshi. 2006;126:209-216.
23. 1A-adrenoceptor antagonist, on the prostatic urethral pressure and blood pressure in male decerebrate dogs. Int J Urol. 2001;8:177-183.
24. 1A-adrenoceptor antagonist silodosin (KMD-3213), a drug for the treatment of voiding dysfunction. Arzneimittelforschung. 2006;56:682-687.
25. Hawrylyshyn KA, Michelotti GA, Coge F, et al. Update on human alpha1-adrenoceptor subtype signaling and genomic organization. Trends Pharmacol Sci. 2004;25:449-455.
26. 1A-blocker improves bladder storage function in rats via suppression of C-fiber afferent activity. World J Urol. 2009 Oct 16. [Epub ahead of print].
27. 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia. Exp Opin Invest Drugs. 2007;16:1955-1965.
28. Montorsi F. Profile of silodosin. Eur Urol Suppl. 2010;9(4):491-495.
29. 1-adrenoceptor antagonist for benign prostatic hyperplasia. Aging Health. 2009;5:459-473.
30. Matsubara Y, Kanazawa T, Kojima Y, et al. Pharmacokinetics and disposition of silodosin (KMD-3213). Yakugaku Zasshi. 2006;126:237-245.
31. 1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: Results of a phase III randomized, placebo-controlled, double blind study in Japanese men. BJU Int. 2006;98:1019-1024.
32. American Urological Association. Results of the treatment outcomes analyses. In: Management of BPH. Available from: http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines. Accessed 2010 Sep 15.
33. 1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: Pooled results of 2 phase 3 studies. J Urol. 2009;181:2634-2640.
34. Marks LS, Gittelman MC, Hill LA, et al. Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: A 9-month, open-label extension study. Urology. 2009;74:1318-1322.
35. 1A-adrenoceptor antagonist, with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men. Urology. 2010;75:520-525.
36. 1-Adrenoceptors and ejaculatory function. Br J Pharmacol. 2007;152:289-290.
37. 1A-blocker in normal volunteers. J Sex Med. 2008;5:2185-2190.
38. Schulman CC. Lower urinary tract symptoms/benign prostatic hyperplasia: Minimizing morbidity caused by treatment. Urology. 2003; 62 Suppl 3A:24-33.
39. 1-adrenoceptor subtype in mRNAs in human vas deferens: Comparison with those of epididymal and pelvic portions. Br J Pharmacol. 1997;122:1009-1014.
40. 1-adrenergic receptor antagonists. Isr Med Assoc J. 2009;11:42-44.
41. 1-adrenoceptor antagonist. Am J Ophthalmol. 2007;143:150-151